Total Payments
$322,883
2024 Payments
$269,950
Companies
10
Transactions
37
Medicare Patients
111
Medicare Billing
$7,239
Payment Breakdown by Category
Research$303,684 (94.1%)
Other$12,432 (3.9%)
Consulting$4,965 (1.5%)
Food & Beverage$1,239 (0.4%)
Travel$562.23 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $303,684 | 9 | 94.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $10,672 | 5 | 3.3% |
| Consulting Fee | $4,965 | 2 | 1.5% |
| Honoraria | $1,760 | 1 | 0.5% |
| Food and Beverage | $1,239 | 17 | 0.4% |
| Travel and Lodging | $562.23 | 3 | 0.2% |
Payments by Type
Research
$303,684
9 transactions
General
$19,199
28 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sumitomo Pharma America, Inc. | $275,437 | 16 | $0 (2024) |
| ADMA BioManufacturing LLC | $34,121 | 3 | $0 (2023) |
| Grifols USA, LLC | $5,654 | 4 | $0 (2024) |
| CSL Behring | $3,750 | 6 | $0 (2023) |
| Horizon Therapeutics plc | $1,760 | 1 | $0 (2020) |
| Shire North American Group Inc | $1,618 | 2 | $0 (2019) |
| Grifols Shared Services North America, Inc. | $200.00 | 1 | $0 (2019) |
| Pharming Healthcare, Inc. | $181.54 | 2 | $0 (2024) |
| Sobi, Inc | $122.88 | 1 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $38.74 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $269,950 | 13 | Sumitomo Pharma America, Inc. ($269,788) |
| 2023 | $7,855 | 9 | Sumitomo Pharma America, Inc. ($5,649) |
| 2022 | $6,673 | 2 | ADMA BioManufacturing LLC ($6,550) |
| 2021 | $29,198 | 4 | ADMA BioManufacturing LLC ($25,651) |
| 2020 | $6,960 | 2 | Grifols USA, LLC ($5,200) |
| 2019 | $678.22 | 5 | Grifols USA, LLC ($362.23) |
| 2017 | $1,569 | 2 | Shire North American Group Inc ($1,530) |
All Payment Transactions
37 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/26/2024 | Sumitomo Pharma America, Inc. | RETHYMIC (Drug) | — | Cash or cash equivalent | $102,774.13 | Research |
| Study: Congenital Athymia Patient Registry • Category: CONGENITAL ATHYMIA | ||||||
| 12/26/2024 | Sumitomo Pharma America, Inc. | RETHYMIC (Drug) | — | Cash or cash equivalent | $39,770.30 | Research |
| Study: Congenital Athymia Patient Registry • Category: CONGENITAL ATHYMIA | ||||||
| 12/26/2024 | Sumitomo Pharma America, Inc. | RETHYMIC (Drug) | — | Cash or cash equivalent | $249.60 | Research |
| Study: Congenital Athymia Patient Registry • Category: CONGENITAL ATHYMIA | ||||||
| 11/15/2024 | Sumitomo Pharma America, Inc. | — | Food and Beverage | In-kind items and services | $29.24 | General |
| 10/25/2024 | Sumitomo Pharma America, Inc. | RETHYMIC (Drug) | — | Cash or cash equivalent | $37,781.31 | Research |
| Study: Congenital Athymia Patient Registry • Category: CONGENITAL ATHYMIA | ||||||
| 10/04/2024 | Sumitomo Pharma America, Inc. | RETHYMIC (Drug) | Food and Beverage | In-kind items and services | $102.91 | General |
| Category: CONGENITAL ATHYMIA | ||||||
| 10/03/2024 | Sumitomo Pharma America, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $33.22 | General |
| 10/03/2024 | Sumitomo Pharma America, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $30.30 | General |
| 10/03/2024 | Sumitomo Pharma America, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $28.96 | General |
| 08/02/2024 | Sumitomo Pharma America, Inc. | RETHYMIC (Drug) | — | Cash or cash equivalent | $57,898.89 | Research |
| Study: Congenital Athymia Patient Registry • Category: CONGENITAL ATHYMIA | ||||||
| 06/07/2024 | Grifols USA, LLC | Xembify (Biological) | Food and Beverage | In-kind items and services | $92.23 | General |
| Category: Immunology and Neurology | ||||||
| 03/20/2024 | Sumitomo Pharma America, Inc. | RETHYMIC (Drug) | — | Cash or cash equivalent | $31,088.85 | Research |
| Study: Congenital Athymia Patient Registry • Category: CONGENITAL ATHYMIA | ||||||
| 01/23/2024 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Food and Beverage | In-kind items and services | $70.31 | General |
| Category: BIOLOGIC | ||||||
| 11/07/2023 | Pharming Healthcare, Inc. | JOENJA (Drug) | Food and Beverage | In-kind items and services | $111.23 | General |
| Category: APDS | ||||||
| 08/19/2023 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $105.92 | General |
| Category: Immunology | ||||||
| 06/23/2023 | Sumitomo Pharma America, Inc. | RETHYMIC (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,380.00 | General |
| Category: CONGENITAL ATHYMIA | ||||||
| 06/23/2023 | Sumitomo Pharma America, Inc. | RETHYMIC (Drug) | Food and Beverage | In-kind items and services | $128.26 | General |
| Category: CONGENITAL ATHYMIA | ||||||
| 06/23/2023 | Sumitomo Pharma America, Inc. | RETHYMIC (Drug) | Food and Beverage | In-kind items and services | $86.72 | General |
| Category: CONGENITAL ATHYMIA | ||||||
| 06/23/2023 | Sumitomo Pharma America, Inc. | RETHYMIC (Drug) | Food and Beverage | In-kind items and services | $4.45 | General |
| Category: CONGENITAL ATHYMIA | ||||||
| 05/19/2023 | Sumitomo Pharma America, Inc. | RETHYMIC (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: CONGENITAL ATHYMIA | ||||||
| 02/20/2023 | ADMA BioManufacturing LLC | Bivigam (Drug) | — | Cash or cash equivalent | $1,920.00 | Research |
| Category: Primary Immunodeficiency Disease | ||||||
| 01/31/2023 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $68.50 | General |
| Category: Immunology | ||||||
| 10/21/2022 | ADMA BioManufacturing LLC | Bivigam (Drug) | — | Cash or cash equivalent | $6,550.00 | Research |
| Study: A Phase IV, Multicenter, Open-label Study to Evaluate the Safety and Pharmacokinetics of BIVIGAM in Primary Immune Deficiency Disorders in Subjects Aged 2 to 16 • Category: Primary Immunodeficiency Disease | ||||||
| 09/14/2022 | Sobi, Inc | GAMIFANT (Drug) | Food and Beverage | In-kind items and services | $122.88 | General |
| Category: HEMATOLOGY | ||||||
| 12/22/2021 | CSL Behring | Privigen (Biological), Hizentra | Consulting Fee | Cash or cash equivalent | $3,435.00 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Congenital Athymia Patient Registry | Sumitomo Pharma America, Inc. | $269,563 | 6 |
| A Multicenter, Non-interventional, Observational, Prospective Study to Assess Hypotension in Patients With Primary Immunodeficiency Disease Treated With Bivigam (Human 10%) or Other Commercial Human 10% Immune Globulin (Intravenous) (IGIV) Products During Infusion and up to 72 Hours Post Infusion (Pass 17) | ADMA BioManufacturing LLC | $25,651 | 1 |
| A Phase IV, Multicenter, Open-label Study to Evaluate the Safety and Pharmacokinetics of BIVIGAM in Primary Immune Deficiency Disorders in Subjects Aged 2 to 16 | ADMA BioManufacturing LLC | $6,550 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 28 | 31 | $35,712 | $1,777 |
| 2022 | 1 | 28 | 30 | $34,560 | $1,814 |
| 2021 | 1 | 26 | 27 | $31,104 | $1,659 |
| 2020 | 1 | 29 | 33 | $38,016 | $1,988 |
Total Patients
111
Total Services
121
Medicare Billing
$7,239
Procedure Codes
4
All Medicare Procedures & Services
4 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 88189 | Flow cytometry technique for dna or cell analysis, 16 or more markers | Facility | 2023 | 28 | 31 | $35,712 | $1,777 | 5.0% |
| 88189 | Flow cytometry technique for dna or cell analysis, 16 or more markers | Facility | 2022 | 28 | 30 | $34,560 | $1,814 | 5.2% |
| 88189 | Flow cytometry technique for dna or cell analysis, 16 or more markers | Facility | 2021 | 26 | 27 | $31,104 | $1,659 | 5.3% |
| 88189 | Flow cytometry technique for dna or cell analysis | Facility | 2020 | 29 | 33 | $38,016 | $1,988 | 5.2% |
About Dr. John Sleasman, MD
Dr. John Sleasman, MD is a Pediatrics healthcare provider based in Durham, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1366453201.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Sleasman, MD has received a total of $322,883 in payments from pharmaceutical and medical device companies, with $269,950 received in 2024. These payments were reported across 37 transactions from 10 companies. The most common payment nature is "" ($303,684).
As a Medicare-enrolled provider, Sleasman has provided services to 111 Medicare beneficiaries, totaling 121 services with total Medicare billing of $7,239. Data is available for 4 years (2020–2023), covering 4 distinct procedure/service records.
Ad
Practice Information
- Specialty Pediatrics
- Other Specialties Pediatric Allergy/Immunology, Pediatric Allergy/Immunology
- Location Durham, NC
- Active Since 08/09/2006
- Last Updated 11/01/2013
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1366453201
Products in Payments
- RETHYMIC (Drug) $275,315
- Bivigam (Drug) $34,121
- Xembify (Biological) $5,492
- Privigen (Biological) $3,435
- ACTIMMUNE (Drug) $1,760
- CUVITRU (Biological) $1,530
- Gamunex-C (Biological) $362.23
- Hizentra (Biological) $224.30
- GAMIFANT (Drug) $122.88
- JOENJA (Drug) $111.23
- CINRYZE (Drug) $87.84
- RUCONEST (Biological) $70.31
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Durham
Dwight Koeberl
Pediatrics — Payments: $8.4M
Pediatrics $8.4M
Priya Kishnani
Pediatrics — Payments: $5.9M
Pediatrics $5.9M
Edward Smith, Md, MD
Pediatrics — Payments: $195,857
Pediatrics $195,857
Dr. Muhammad Zafar, M.d, M.D
Pediatrics — Payments: $158,957
Pediatrics $158,957
Jennifer Li, Md, MD
Pediatrics — Payments: $55,856
Pediatrics $55,856
Sarah Armstrong, Md, MD
Pediatrics — Payments: $46,142
Pediatrics $46,142